Brief about Subcutaneous Biologics and its uses

A biologic, usually referred to as a biopharmaceutical, is a complex therapeutic product created through a biological process. Blood and plasma-derived products, vaccinations, somatic cells, and body proteins are all examples of biologics. The term "biologics" refers to a multibillion-dollar industry that is growing at a rapid pace around the world. The majority of biologics are administered intravenously. However, in recent years, a number of biologics that are administered subcutaneously have been created. The subcutaneous route of administration has several advantages over intravenous administration, including ease of drug administration, the lack of skilled personnel required for drug administration, the ability to deliver drugs at home, which reduces patient time in healthcare facilities, lower medicine costs, and increased therapy compliance. The subcutaneous route of administration has exploded in popularity in recent years due to the aforementioned characteristics. Subcutaneous injection of biologics such as vaccines, proteins, peptides, antibodies, and other large and complicated molecules is extremely successful.

According to the "Coherent Market Insights" Global Industry Insights, Trends, Outlook, and Opportunity Analysis of Subcutaneous Biologics Market.

Subcutaneous Biologics Market

Overall, statistics show that subcutaneous administration is easier than intravenous infusions, that it can lower medication delivery-related healthcare costs and resources, and that it is widely favoured by patients and HCPs. Because subcutaneous tissue contains few blood arteries, the injected medicine diffuses slowly and at a steady rate. As a result, it's ideal for giving vaccinations, growth hormones, and insulin, which need to be delivered in a steady stream at a low dose rate.

A subcutaneous injection is a needle-based method of administering certain drugs. The innermost (deepest) layer of skin is the subcutaneous tissue, commonly known as the hypodermis. It is made primarily of fat and connective tissue and aids in temperature regulation. The research by Vermeire establishing the efficacy and safety of a novel vedolizumab subcutaneous [SC] formulation in Crohn's disease piqued our interest. The majority of the known research focuses on the medical implications of moving to SC formulations. The patient's part in the switching process is underappreciated, despite the fact that it is one of the most important aspects.

The propensity of patients with inflammatory bowel disease to transition from intravenous to SC medication was assessed in a pilot study at our centre. Between December 1, 2020, and February 28, 2021, all patients who had IV treatment for at least 6 weeks were asked to complete a questionnaire. All patients were informed about the future SC options, the new care route, and the survey questions that will be asked.